United States - English - NLM (National Library of Medicine)

ropack inc. - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) - secnidazole 2 g in 4.8 g - solosec is indicated for the treatment of bacterial vaginosis in adult women [see use in specific populations ( 8.1) and clinical studies ( 14)]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of solosec and other antibacterial drugs, solosec should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hypersensitivity solosec is contraindicated in patients who have shown hypersensitivity to secnidazole, other ingredients of the formulation, or other nitroimidazole derivatives. risk summary limited available data with solosec use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. in animal reproducti

Kenya - English - Pharmacy and Poisons Board

lincoln pharmaceuticals ltd c/o medox… p.o. box 52771 - 00200 - secnidazole - film-coated tablet - secnidazole 1 gm - secnidazole

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) -

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) - secnidazole 2 g in 4.8 g - solosec is indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older [see use in specific populations (8.1) and clinical studies (14)]. solosec is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis in patients 12 years of age and older.  because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, treat partners of infected patients simultaneously in order to prevent reinfection [see dosage and administration (2.2)  and  clinical studies (14.2)] . to reduce the development of drug-resistant bacteria and maintain the effectiveness of solosec and other antibacterial drugs, solosec should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) -

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) -

United States - English - NLM (National Library of Medicine)

evereen shanghai biotechnology ltd. - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) -

United States - English - NLM (National Library of Medicine)

symbiomix therapeutics - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) - secnidazole 2 g in 4.8 g

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) - secnidazole 495 g in 1 g

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - secnidazole (unii: r3459k699k) (secnidazole - unii:r3459k699k) -